New hope for gastric cancer patients: drug may curb chemo weight loss
NCT ID NCT07581405
First seen May 18, 2026 · Last updated May 22, 2026 · Updated 1 time
Summary
This study tests whether a low dose of olanzapine, a drug often used for nausea, can help people with stomach cancer maintain their weight and appetite while receiving chemotherapy before surgery. About 26 participants will be randomly assigned to receive either olanzapine plus standard care or standard care alone. The goal is to improve nutrition and quality of life during treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.